miR-103a-3p Suppresses Cell Proliferation and Invasion by Targeting Tumor Protein D52 in Prostate Cancer

References

• Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer. 2015;51(9):1164–1187. doi:10.1016/j.ejca.2013.09.002.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5(12):1749–1768. doi:10.1001/jamaoncol.2019.2996.
   PubMed Web of Science ®Google Scholar
• Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol. 2011;8(6):357–368. doi:10.1038/nrclinonc.2011.67.
   PubMed Web of Science ®Google Scholar
• Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009;56(4):594–605. doi:10.1016/j.eururo.2009.06.027.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi:10.1016/S0092-8674(04)00045-5.
   PubMed Web of Science ®Google Scholar
• Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6(6):590–610. doi:10.1016/j.molonc.2012.09.006.
   PubMed Web of Science ®Google Scholar
• Aghdam AM, Amiri A, Salarinia R, Masoudifar A, Ghasemi F, Mirzaei H. MicroRNAs as diagnostic, prognostic, and therapeutic biomarkers in prostate cancer. Crit Rev Eukaryot Gene Expr. 2019;29(2):127–139. doi:10.1615/CritRevEukaryotGeneExpr.2019025273.
   PubMed Web of Science ®Google Scholar
• Roslan N, Bièche I, Bright RK, Lidereau R, Chen Y, Byrne JA. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinog. 2014;53(10):807–819. doi:10.1002/mc.22038.
   PubMed Web of Science ®Google Scholar
• van Duin M, van Marion R, Vissers K, et al. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosom Cancer. 2005;44(4):438–449. doi:10.1002/gcc.20259.
   PubMed Web of Science ®Google Scholar
• Dasari C, Yaghnam DP, Walther R, Ummanni R. Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-κB transactivation in LNCaP cells. Tumour Biol. 2017;39(5):101042831769838. doi:10.1177/1010428317698382.
   Google Scholar
• Goto Y, Nishikawa R, Kojima S, et al. Tumor-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett. 2014;588(10):1973–1982. doi:10.1016/j.febslet.2014.04.020.
   PubMed Web of Science ®Google Scholar
• Han G, Fan M, Zhang X. microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression. Biochem Biophys Res Commun. 2015;456(3):804–809. doi:10.1016/j.bbrc.2014.12.026.
   PubMed Web of Science ®Google Scholar
• Moritz T, Venz S, Junker H, Kreuz S, Walther R, Zimmermann U. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells. Tumor Biol. 2016;37(8):10435–10446. doi:10.1007/s13277-016-4925-1.
   PubMedGoogle Scholar
• Rubin MA, Varambally S, Beroukhim R, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 2004;64(11):3814–3822. doi:10.1158/0008-5472.CAN-03-3881.
   PubMed Web of Science ®Google Scholar
• Sur S, Steele R, Shi X, Ray RB. miRNA-29b inhibits prostate tumor growth and induces apoptosis by increasing Bim expression. Cells. 2019;8(11):1455. doi:10.3390/cells8111455.
   PubMed Web of Science ®Google Scholar
• Keller ET, Dai J, Escara-Wilke J, et al. New trends in the treatment of bone metastasis. J Cell Biochem. 2007;102(5):1095–1102. doi:10.1002/jcb.21540.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Birzele F, Kollmorgen G, Rüger R. Molecular mechanisms of bone metastasis. Cancer Genomics Proteomics. 2016;13(1):1–12. doi:10.21873/cgp.20015.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis. 2012;33(6):1126–1133. doi:10.1093/carcin/bgs140.
   PubMed Web of Science ®Google Scholar
• Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One. 2013;8(12):e83991. doi:10.1371/journal.pone.0083991.
   PubMed Web of Science ®Google Scholar
• Fuse M, Nohata N, Kojima S, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38(4):1093–1101. doi:10.3892/ijo.2011.919.
   PubMed Web of Science ®Google Scholar
• Nishikawa R, Goto Y, Kojima S, et al. Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. Int J Oncol. 2014;45(1):401–410. doi:10.3892/ijo.2014.2437.
   PubMed Web of Science ®Google Scholar
• Fu X, Zhang W, Su Y, Lu L, Wang D, Wang H. MicroRNA‐103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer. Prostate. 2016;76(6):543–551. doi:10.1002/pros.23143.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Lv M, Chen J. Screening differential circular RNA expression profiles reveals the regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in bladder carcinoma. Sci Rep. 2016;6(1):30919. doi:10.1038/srep30919.
   PubMed Web of Science ®Google Scholar
• Hu X, Miao J, Zhang M, et al. miRNA-103a-3p promotes human gastric cancer cell proliferation by targeting and suppressing ATF7 in vitro. Mol Cells. 2018;41(5):390–400. doi:10.14348/molcells.2018.2078.
   PubMed Web of Science ®Google Scholar
• Chang JT, Wang F, Chapin W, Huang RS. Identification of microRNAs as breast cancer prognosis markers through the Cancer Genome Atlas. PLoS One. 2016;11(12):e0168284. doi:10.1371/journal.pone.0168284.
   PubMed Web of Science ®Google Scholar
• Bignotti E, Calza S, Tassi RA, et al. Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. J Cell Mol Med. 2016;20(12):2341–2348. doi:10.1111/jcmm.12927.
   PubMed Web of Science ®Google Scholar
• Hamaya Y, Kuriyama S, Takai T, et al. A distinct expression pattern of the long 3′-untranslated region dicer mRNA and its implications for posttranscriptional regulation in colorectal cancer. Clin Transl Gastroenterol. 2012;3(7):e17. doi:10.1038/ctg.2012.12.
   PubMed Web of Science ®Google Scholar
• Vigneri P, Martorana F, Manzella L, Stella S. Biomarkers and prognostic factors for malignant pleural mesothelioma. Future Oncol. 2015;11(24s):29–33. doi:10.2217/fon.15.317.
   PubMed Web of Science ®Google Scholar
• Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102–114. doi:10.1038/nrg2290.
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008;19(1):92–105. doi:10.1101/gr.082701.108.
   PubMed Web of Science ®Google Scholar
• Shridhar V, Lee J, Pandita A, et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001;61(15):5895–5904.
   PubMed Web of Science ®Google Scholar
• Terada N, Kamoto T, Tsukino H, et al. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients. BMC Cancer. 2019;19(1):156. doi:10.1186/s12885-019-5342-9.
   PubMed Web of Science ®Google Scholar